Group 7 Copy 3 Created with Sketch.

MENU
Centers
Carotid Coding Dialysis Embolization EVAR HTN Limb Salvage Neurointervention Oncology Radial Regulatory Renal SFA TEVAR Venous
News Current Issue Archive Device Guide Calendar Subscribe Advertising About Contact Privacy Submissions

Advertisement

Search Results

Refine by Content Type

close Created with Sketch.

Refine by Year

close Created with Sketch.

Sort By:

Relevance Date

Choose Sites to Search:

EVToday EVToday + CIToday

evt | Article | June 2014

When Not to Perform Percutaneous Thrombectomy of a Clotted Native Fistula

Ten scenarios in which this therapy may not be the best option for hemodialysis fistula treatment.

By Jonas W. Redmond, MD, and Timothy W.I. Clark, MD, FSIR

evt | Article | June 2014

When Not to Perform Percutaneous Thrombectomy of a Clotted Native Fistula

Ten scenarios in which this therapy may not be the best option for hemodialysis fistula treatment.

By Jonas W. Redmond, MD, and Timothy W.I. Clark, MD, FSIR

evt | Article | June 2015

What's New in Declots? Management of the Total Access Thrombosis Patient

An alternative technique to catheter-directed thrombolysis in the patient undergoing dialysis.

By Nicholas J. Petruzzi, MD; Jonas W. Redmond, MD; and Timothy W.I. Clark, MD, FSIR

evt | News | March 18, 2015

Commercialization Agreement Announced for Forge Medical's VasoStat Hemostasis Device

March 19, 2015—Forge Medical, Inc., manufacturer of the VasoStat hemostasis device announced that the company had entered into a national commercialization agreement for the device with National Medical Sales LLC, a United States distributor of interventional and vascular specialty products.

Advertisement

evt | News | January 6, 2016

Forge Medical's VasoStat Hemostasis Device Cleared for Pedal and Tibial Applications

January 7, 2016—Forge Medical, Inc. announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for expanded indications of the company’s VasoStat hemostasis device to include pedal and tibial hemostasis.

evt | Article | June 2015

An Opportunity to Look Into the Future of Hemodialysis
Access

By Bart Dolmatch, MD, FSIR

evt | News | February 9, 2024

Study Examines Effect of ESRD on Limb Events and Amputation Risk in CLI Patients

February 9, 2024—In a retrospective, observational cohort study of patients with critical limb ischemia (CLI) who underwent tibial peripheral vascular intervention (PVI), those with end-stage renal disease (ESRD) were more likely to experience major adverse limb events (MALEs) and undergo major amputation as compared with those without ESRD.

Advertisement

Cardiac Interventions Today
Group 7 Copy 3 Created with Sketch.
bmc-secondary-mark-color copy Created with Sketch.

© 2026 Bryn Mawr Communications II, LLC.  
All Rights Reserved   •   Privacy Policy

one-trust-button